6 ms·
It may not have been that high, but I remember being surprised by how much higher than physiological temperature. The FDA is doing a great job keeping the publ
by refurb 7y ago
It may not have been that high, but I remember being surprised by how much higher than physiological temperature.
The FDA is doing a great job keeping the public informed.
https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine https://www.fda.gov/drugs/drug-safety-and-availability/fda-u...
Check out the 10/2 update with regards to temperature. Here is the relevant part:
FDA observed the testing method used by a third-party laboratory uses higher temperatures. The higher temperatures generated very high levels of NDMA from ranitidine products because of the test procedure. FDA published the method for testing angiotensin II receptor blockers (ARBs) for nitrosamine impurities. That method is not suitable for testing ranitidine because heating the sample generates NDMA.
To Valisure’s credit they are posting their data.
https://www.valisure.com/wp-content/uploads/Attachment-B-GC-MS-Ranitidine-Data-Report_v6.2.pdf https://www.valisure.com/wp-content/uploads/Attachment-B-GC-...
However, they are using GC/MS, which typically had pre-column temperatures of >150C (since all analyses need to be in the gas phase). Plenty of drugs decompose at those temperatures. That’s why the FDA doesn’t recommend it.